Yahoo Finance Is Nymox Pharmaceutical Corporation's (NASDAQ:NYMX) CEO Being Overpaid?
The CEO of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is Paul Averback. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. After that, we will consider the growth in the business. Third, we'll reflect on the total return to shareholders over three years, as a second measure of business performance. This process should give us an idea about how appropriately the CEO is paid.
View our latest analysis for Nymox Pharmaceutical
How Does Paul Averback's Compensation Compare With Similar Sized Companies?
According to our data, Nymox Pharmaceutical Corporation has a market capitalization of US$259m, and paid its CEO total annual compensation worth US$1.5m over the year to December 2018. While we always look at total compensation first, we note that the salary component is less, at US$600k. We looked at a group of companies with market capitalizations from US$100m to US$400m, and the median CEO total compensation was US$1.1m.
As you can see, Paul Averback is paid more than the median CEO pay at companies of a similar size, in the same market. However, this does not necessarily mean Nymox Pharmaceutical Corporation is paying too much. We can get a better idea of how generous the pay is by looking at the performance of the underlying business.
You can see a visual representation of the CEO compensation at Nymox Pharmaceutical, below.
Is Nymox Pharmaceutical Corporation Growing?
On average over the last three years, Nymox Pharmaceutical Corporation has grown earnings per share (EPS) by 18% each year (using a line of best fit). In the last year, its revenue is down 72%.
This shows that the company has improved itself over the last few years. Good news for shareholders. The lack of revenue growth isn't ideal, but it is the bottom line that counts most in business. We don't have analyst forecasts, but you could get a better understanding of its growth by checking out this more detailed historical graph of earnings, revenue and cash flow.
Has Nymox Pharmaceutical Corporation Been A Good Investment?
With a total shareholder return of 1.6% over three years, Nymox Pharmaceutical Corporation has done okay by shareholders. But they probably don't want to see the CEO paid more than is normal for companies around the same size.
In Summary...
We compared the total CEO remuneration paid by Nymox Pharmaceutical Corporation, and compared it to remuneration at a group of similar sized companies. We found that it pays well over the median amount paid in the benchmark group.
However we must not forget that the EPS growth has been very strong over three years. Looking at the same time period, we think that the shareholder returns are respectable. You might wish to research management further, but on this analysis, considering the EPS growth, we wouldn't call the CEO pay problematic. Shareholders may want to check for free if Nymox Pharmaceutical insiders are buying or selling shares.
Arguably, business quality is much more important than CEO compensation levels. So check out this free list of interesting companies, that have HIGH return on equity and low debt.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
